Milton C. Ault III Sells 29,449 Shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) Stock

Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Milton C. Ault III sold 29,449 shares of Alzamend Neuro stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $2.51, for a total transaction of $73,916.99. Following the sale, the director owned 108,260 shares of the company’s stock, valued at approximately $271,732.60. The trade was a 21.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Alzamend Neuro Stock Performance

NASDAQ ALZN opened at $2.20 on Monday. The stock’s 50-day simple moving average is $3.18 and its two-hundred day simple moving average is $6.08. Alzamend Neuro, Inc. has a twelve month low of $2.06 and a twelve month high of $135.54.

Hedge Funds Weigh In On Alzamend Neuro

A hedge fund recently bought a new stake in Alzamend Neuro stock. Citadel Advisors LLC purchased a new stake in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned about 0.56% of Alzamend Neuro at the end of the most recent reporting period. 49.61% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised shares of Alzamend Neuro from a “sell” rating to a “hold” rating in a report on Saturday, June 14th.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.